Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

F2G Ltd.

www.f2g.com

Latest From F2G Ltd.

US FDA's Antimicrobial Head Ed Cox Leaves For Regeneron; Agency Needs New LPAD Champion

Long-time deputy John Farley becomes acting director of the Office of Antimicrobial Products. Cox, who served as the director of the office for more than a decade, joins Regeneron to serve as vice president of regulatory affairs.

FDA Leadership

Antibiotic Stakeholders Discuss Ethics Of Testing Limited Population Drugs In Broader Populations

The US FDA's LPAD draft guidance suggests that clinical trials for potential limited population antibacterials would enroll broader patient populations. But is that an ethical approach?

Clinical Trials Infectious Diseases

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs

European Loan Funds F2G's Late-Stage Novel Antifungal

€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.

Financing Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • F2G Ltd.
  • Senior Management
  • Ian Nicholson, CEO
    Ralf Schmid, CFO
    Mike Birch, PhD, COO
    Tony Kennedy, Chief Scientific & Dev. Officer
  • Contact Info
  • F2G Ltd.
    Phone: (44) 161 785 1270
    Lankro Way
    Eccles
    Manchester, M30 0LX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register